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ABSTRACT  1 
Many animal studies have reported an association between melatonin suppression and the 2 
disturbance of metabolic responses, yet few human studies have investigated bright light 3 
effects on metabolic and hormonal responses at night. This study investigated the impact of 4 
light on plasma hormones and metabolites prior to, and after, an evening meal in healthy 5 
participants. Seventeen healthy participants, 8 females (22.2 ± 2.59 years, mean ± SD), 9 6 
males (22.8 ± 3.5 years) were randomised to a two way cross over design protocol; dim light 7 
(DL) (<5 lux) and bright light (BL) (>500 lux) sessions, separated by at least seven days. 8 
Saliva and plasma samples were collected prior to and after a standard evening meal at specific 9 
time intervals. Plasma non-esterified fatty acid (NEFA) levels were significantly higher pre-10 
meal in DL compared to BL (P < 0.01). Plasma glucose and insulin levels were significantly 11 
greater post-meal in the BL compared to DL session (P = 0.02, P = 0.001) respectively. 12 
Salivary melatonin levels were significantly higher in the DL compared to BL session (P = 13 
0.005). 14 
BL at night was associated with significant increases in plasma glucose and insulin suggestive 15 
of glucose intolerance and insulin insensitivity. Raised pre-prandial NEFA levels may be due 16 
to changes in insulin sensitivity or the presence of melatonin and/or light at night. Plasma 17 
triglyceride levels were the same in both sessions. These results may explain some of the 18 
health issues reported in shift workers however further studies are needed to elucidate the 19 
cause of these metabolic changes.  20 
21 
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INTRODUCTION 22 
Artificial light exposure at night has become commonplace throughout the developed world 23 
(1,2).  Light has been linked to various complex mechanisms such as the synchronization of 24 
the circadian system(3). Circadian rhythms are seen in any biological processes that display an 25 
endogenous oscillation of about 24 hours. They are generated by the suprachiasmatic nuclei 26 
(SCN) located in the anterior hypothalamus, and influenced by external cues called zeitgebers 27 
(commonly daylight). Melatonin is considered the classical phase marker for assessing the 28 
timing of the mammalian biological clock.  The SCN drives the daily rhythms in hormone 29 
concentrations such as insulin, glucagon, corticosterone (4-6) and enzymes involved in lipid 30 
and glucose metabolism, such as glucose-6-phosphate dehydrogenase (7,8). Therefore, 31 
disruption of circadian coordination may be manifested by endocrine imbalances (9), 32 
incidence of obesity (10) and type 2 diabetes (11,12). This raises a controversial issue as to 33 
whether aberrant light exposure may influence metabolism by changing the time of the 34 
circadian system (13). It has been reported that blood glucose increases during light exposure 35 
and decreases during darkness in rats (14,15). Others have reported the melatonin-induced 36 
inhibition of insulin secretion via cyclic adenosine monophosphate (cAMP) and cyclic guanine 37 
monophosphate (cGMP), and the presence of melatonin receptors 1(MT1) and 2(MT2) in 38 
pancreatic tissues of  both rats and humans(16). Additionally, acute melatonin administration 39 
in healthy women has been reported to impaired glucose tolerance in both the morning and 40 
evening(17). The impact of melatonin administration on lipid metabolism has been 41 
demonstrated in experimental animals (18,19) and humans (20,21). In addition, melatonin has 42 
been reported to influence insulin (16) and glucagon (22) which in turn affect enzymes 43 
involved in lipid metabolism such as hormone sensitive lipase (HSL) and lipoprotein lipase 44 
(LPL). 45 
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A majority of the previous studies investigating the effect of light on hormone and metabolic 46 
responses have either been carried out on experimental animals (14), or under restricted 47 
conditions in humans such as constant routine (16,23,24) including the administration of 48 
exogenous melatonin (17,21).The aim of this study was to investigate the impact of broad 49 
spectrum bright light exposure (>500 lux) on healthy young participants prior to and after a 50 
late evening meal. This study may have implications for those living a nocturnal lifestyle such 51 
as shift-workers, and may, in part, explain some of the health issues associated with working 52 
shifts. We hypothesise that a single night light exposure is associated with changes in glucose 53 
tolerance, insulin sensitivity and lipid profiles.  54 
PARTICIPANTS AND METHODS 55 
Recruitment 56 
All procedures received a favourable ethical opinion from the University of Surrey Ethics 57 
Committee (UEC/2013/93/FHMS) and were conducted in accordance with the declaration of 58 
Helsinki (1975) as revised in 1983, and conformed to international ethical standards. 59 
Volunteer information was coded and held securely in compliance with the Data Protection 60 
Act, UK (1998). All participants gave written informed consent after full explanation of the 61 
purpose and nature of all procedures involved. 62 
Participants and screening 63 
Seventeen healthy participants, 8 females (22.2 ± 2.59 years; mean ± SD) and 9 males (22.8 ± 64 
3.5 years) were recruited from students and staff at the University of Surrey. The two genders 65 
were matched for age and body mass index (BMI) (Table 1). Participants were all non-66 
smokers and taking no medication except for mild analgesics. All females were on oral 67 
contraceptive pills. Participants had not crossed more than two time zones and/or worked night 68 
shifts during the month before the study. All participants completed screening questionnaires 69 
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including Pittsburgh Sleep Quality Index (PSQI), Horne-Östberg (HÖ) and Munich 70 
chronotype.  71 
Pre-laboratory measurements 72 
All participants maintained a standard self-selected regular sleep-wake cycle (nocturnal sleep 73 
duration of 6.5 to 8h, with sleep onset between 23:00h to 01:00h) for at least 7 days before the 74 
in-laboratory sessions, as confirmed by actigraphy (AWL, Cambridge Neurotechnology, UK) 75 
and sleep diaries (Table 2). 24-h prior to the laboratory sessions, participants were required to 76 
refrain from caffeinated drinks, alcohol, excessive exercise and medicine intake. In addition, 77 
participants performed a 48-h sequential urine collection to measure 6-sulfatoxymelatonin 78 
(αMT6s), the major urinary metabolite of melatonin, via radioimmunoassay (Stockgrand Ltd., 79 
University of Surrey, Guildford,UK). The acrophase of 6-sulfatoxymelatonin was determined 80 
by cosinor analysis, enabling meal intakes (supper) to be individually scheduled to occur on 81 
the rising phase of each participants’ endogenous melatonin rhythm.  82 
Laboratory session 83 
All participants were randomised to a two way cross over design protocol; dim light and bright 84 
light. All study sessions were held at the Clinical Investigation Unit (CIU) which was 85 
equipped with overhead light control. During the dim-light session, lighting levels were <5 lux 86 
and in the bright-light session, lighting was >500 lux between 18:00h and 06:00h the next day 87 
(Figure 1). Participants were randomly coded alphanumerically divided into groups A and B 88 
using the sealed envelope method. Group A attended BL session and then the DL session, 89 
while group B completed the sessions in reverse order. Participants were kept awake and semi-90 
recumbent throughout the study session, except during visits to the toilet. A set breakfast was 91 
provided at 08:00h, whereas lunch and supper (test meal) times were individualised on the 92 
basis of the acrophase time of urinary aMT6s. The fasting period between lunch and supper 93 
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was 9-10 hours. Participants consumed an isocaloric and non-carbonated evening meal at a 94 
time estimated to be within 30 mins of endogenous melatonin onset (1066 Kcal, 38g protein, 95 
104g CHO, 54g fat,  7g fibre) (Table 3). 96 
Blood samples were collected hourly from 18:00h until the evening meal; then every 15 97 
minutes for the first hour after the meal, then at 30 minutes intervals until the end of the 98 
session. In total, 22 blood samples were collected in each session from each participant for 99 
analysis of insulin, glucose, TAG and NEFAs. Saliva samples were collected every 30 minutes 100 
from 18:00h to 06:00h the following day for analysis of melatonin levels. 101 
Light measurements 102 
Light intensity was measured at 2 different positions horizontal level (direction of gaze) (n = 103 
221; DL 1.06 ± 0.06 lux, BL 305 ± 10.1 lux; mean ± SEM) and vertical level towards the 104 
lights (n = 221; DL 1.21 ± 0.13, BL 552.7 ± 16; mean ± SEM).  105 
Spectral composition of the light source was measured using a R203 power radiometer at 106 
horizontal (DL 0.001 w/m2, BL 0.98 w/m2 and vertical level (DL 0.0008 w/m2, BL 0.73 w/m2). 107 
The light source provided in both studies are fluorescent light, and the spectral composition of 108 
the light is shown in Figure 2. 109 
Assay procedures 110 
Plasma glucose, TAG (Werfen Ltd, Warrington, UK) and NEFAs (Randox Laboratories Ltd, 111 
Crumlin, UK) were analysed by standard automated enzymatic spectrophotometric methods 112 
(ILAB600). The interassay coefficients of variation were less than 5% for glucose, NEFAs and 113 
TAGs. Plasma immunoreactive insulin was measured using radioimmunoassay (RIA) 114 
(Millipore Ltd, Hertfordshire, UK). Salivary melatonin and urinary aMT6s were analysed 115 
using in-house RIAs (25,26). The interassay coefficients of variation were less than 10% for 116 
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melatonin (control 1 = 6.5pg/ml (6.7%), control 2 = 24.5 (6.7%), and control 3 = 49.6pg/ml 117 
(6.8%) and insulin (control 1= 100.3pmol/L (10%), and control 2= 332.2pmol/L (9.5%). 118 
Measurement of insulin resistance 119 
An index of fasting insulin resistance (HOMA-IR) and postprandial insulin resistance 120 
(HOMA-PP) were determined for the evening meal in both BL and DL sessions. 121 
HOMA-IR was calculated using the HOMA calculator based on HOMA model 2 developed by 122 
Jonathan Levy (27). 123 
HOMA-PP was calculated as the incremental area under the curve (IAUC) glucose 124 
(mmol/l.min) X IAUC insulin (mU/l.min).  125 
This equation has been validated against the intravenous glucose tolerance (28). 126 
Data and statistical analysis  127 
A power calculation was performed using PS software (Vanderbilt University, Tennessee, US) 128 
with a power of 80% and a significance level 0.05 utilising NEFA data obtained from a 129 
previous pilot investigation. From this power calculation, ≥18participants were required. 130 
Urine aMT6s data was subjected to cosinor analysis (Dr D S Minors at the University of 131 
Manchester, UK), to ascertain calculated peak time of aMT6s (acrophase). 132 
All data were checked for normality using D’Agostino Pearson omnibus normality test 133 
(Graphpad, San Diego, CA, USA). The mean value plus the standard deviation (SD) and 134 
standard error of mean (SEM) were calculated from individual data sets. All hormonal and 135 
metabolic data were subjected to three factor repeated measures ANOVA (condition, gender 136 
and time) followed by Tukey’s honest significance post-hoc test to locate individual 137 
differences, using Statistica Statsoft (Tulsa OK, USA). The trapezoidal rule was used to 138 
determine the total area under curve (TAUC). All hormone and metabolite data were analysed 139 
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using TAUC, followed by 2-tailed paired student’s t-test. The significance level was set at P < 140 
0.05.  141 
RESULTS 142 
Comparison of male and female participants 143 
The mean age, body weight, height and BMI of 9 males and 8 females in this study were 144 
matched (Table 1). Caffeine and alcohol consumption over the two weeks prior to the study 145 
were not significantly different between male and female groups. Both genders were classified 146 
as neither morning nor evening types by the HÖ, and all reported a good sleep quality over a 147 
month prior to the study using the PSQI. Sleep parameters screened prior to BL and DL 148 
sessions are given in Table 2. Participants reported no significant difference in sleep prior to 149 
BL and DL sessions. No differences were observed in hormone and metabolic concentrations 150 
at the start of the each study session (Table 2). 151 
Plasma levels prior to the test meal (T = 0) 152 
Basal levels of plasma insulin, glucose, TAGs and NEFAs from samples collected 153 
immediately prior to the meal (T = 0) are shown in Figure 3. Basal glucose and insulin 154 
showed no significant differences between BL and DL sessions. Basal NEFAs were 155 
significantly higher in DL than BL (P = 0.02). No significant difference was seen in basal 156 
TAGs between DL and BL (P = 0.81). Basal melatonin levels were significantly greater in DL 157 
than in BL (P< 0.001) (Figure 2). 158 
Hormone and metabolic responses prior to the meal (T-360-0) 159 
There were no significant differences between BL and DL sessions in plasma glucose, insulin 160 
and TAGs concentrations prior to evening meal. Pre-evening meal NEFAs showed a 161 
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significant increase in DL compared to BL session (P =0.03). Similarly, salivary melatonin 162 
was significantly higher in the DL session (P < 0.001) (Figure 4). 163 
Postprandial hormone and metabolic responses 164 
Postprandial plasma glucose and insulin responses to the test meal showed a significant 165 
increase in BL compared to DL (P = 0.01, P = 0.008) respectively. Salivary melatonin was 166 
significantly greater in DL than in BL sessions (P< 0.001). There were no differences in 167 
postprandial TAGs responses after BL and DL sessions (Figure 3). 168 
Pre and Postprandial hormone and metabolic responses (T = -360 to T = +330) 169 
Graphical representations of the female, male and all participants during DL and BL sessions 170 
are shown in Figure 3. Plasma insulin levels were significantly greater in BL than in DL 171 
sessions (P = 0.001). Post-hoc tests showed significant differences at +180, +210 and +270 172 
min. Similarly, plasma glucose showed a significant increase in BL compared to DL sessions 173 
(P = 0.02). Post-hoc test showed significant differences at +180 and +210 min after the meal. 174 
In contrast, there was a significant pre-prandial increase of plasma NEFA in DL session (P = 175 
0.005). Post-hoc tests showed the difference was directly prior to the evening meal (T = 0). 176 
Plasma TAGs showed no significant difference between the DL and BL sessions. All 4 plasma 177 
parameters showed significant effects of time, whereas no significant effects of gender were 178 
observed. 179 
Salivary melatonin levels were significantly greater in DL than in BL session (P< 0.001). Post-180 
hoc tests showed significant differences at pre-prandial and postprandial time points between   181 
-120 to +330 min. Both males and females show similar increase in salivary melatonin in DL 182 
compared to BL sessions, females showed higher levels of salivary melatonin than males 183 
although not significant (Figure 4).  184 
 185 
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Total area under the curve 186 
TAUCs for, insulin, glucose, NEFAs, TAGs and melatonin were calculated, and are shown in 187 
Figure 5. TAUCs for NEFAs showed a significant reduction in BL (290 ± 17mmol/l.min) 188 
compared to DL (350 ± 18. mmol/l.min) sessions (P = 0.009).  In contrast, a significant 189 
increase in TAUCs for plasma insulin and glucose were shown in BL compared to DL (P = 190 
0.004 and P = 0.03) respectively. TAUC of plasma insulin was 129119 ± 10343 pmol/l.min in 191 
DL and 109875 ± 9817 pmol/l.minin BL, whereas TAUCs of plasma glucose were 3805.76 ± 192 
60 mmol/l.min in DL and 3985 ± 73 mmol/l.min in BL. No significant difference was 193 
observed in plasma TAGs responses. TAUCs showed a significant suppression of salivary 194 
melatonin in BL compared to DL sessions (P < 0.0001), TAUCs were 3171 ± 530 pg/ml.min 195 
in BL session and 10362 ± 1777 pg/ml.min in DL sessions. 196 
HOMA-PP and HOMA-IR 197 
HOMA-PP and HOMA-IR are shown in Figure 6. HOMA-PP was greater but not significant 198 
in BL (49802 ± 6428) than DL (41607 ± 6141) session. Similarly, HOMA-IR was higher, yet 199 
not significantly, in BL (1.2 ± 0.1) compared to DL (1.1 ± 0.1) sessions. 200 
DISCUSSION 201 
Few studies have investigated the influence of light at night on plasma hormones and 202 
metabolites in healthy humans, since a majority of the studies reported have either been carried 203 
out on experimental animals (29) or under restricted conditions in humans such as constant 204 
routine (16,23,30,31) or involved the administration of exogenous melatonin (19,20). To the 205 
author’s knowledge this is the first study to investigate bright light exposure at night on 206 
hormonal and metabolic responses prior to and after a standard evening meal in healthy young 207 
individuals by exposing them to two light sessions: bright (> 500lux), equivalent to light the 208 
intensity in the workplace, and dim light (<5 lux) equivalent to candle light. 209 
Females Males 
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The salivary melatonin profile was significantly reduced by bright light exposure at night. This 210 
was expected as the light intensity delivered at the angle of gaze was 305 lux, and previous 211 
human studies have shown that 200 lux was sufficient to suppress salivary melatonin by 50% 212 
in healthy participants (32). In this study, a reduction of 62% in melatonin amplitude was 213 
observed in the BL session. The evening meal was targeted between 30min to 1h after 214 
estimated melatonin onset in both light sessions to ensure the presence of endogenous 215 
melatonin at the meal time. All participants showed the presence of endogenous melatonin at 216 
evening meal time in DL session. Our results indicate that salivary melatonin levels appear 217 
higher, but not statistically significant, in females than in males under both light sessions 218 
agreeing with previously published research (33).  219 
Plasma glucose responses were significantly elevated three hours after the meal in the BL 220 
session, confirmed by TAUC analysis. Insulin levels were significantly elevated after the meal 221 
in BL compared to the DL sessions. Raised glucose and insulin responses suggest changes in 222 
glucose tolerance and insulin sensitivity. Calculation of HOMA-PP and HOMA–IR confirmed 223 
these findings although significance was not achieved. Our present study agrees with studies  in 224 
rats and mice that showed decreased blood glucose and insulin in constant darkness (14,15). 225 
Fonken et al. (2010) observed  that male mice exposed to constant light increased body mass 226 
and reduced glucose tolerance compared to standard light/dark cycle (34).  It is an important 227 
caveat to note the differences between nocturnal and diurnal mammals in rest/activity cycles, as 228 
well as the opposite phases rhythms of hormones and glucose known as 12-h reversal hormonal 229 
rhythms, with the exception of the melatonin rise which occurs in both diurnal and nocturnal 230 
species. Difference in sleep/wake cycles between nocturnally animals and diurnally human has 231 
been associated with opposite phase rhythms of hormones important in metabolism regulation 232 
(35), despite the similarity in melatonin rhythms in both species.  Our results are also in 233 
agreement with recent evidence observed in sleep deprivation (23,36,37) and circadian 234 
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misalignment (31,38) such as in jet lag and shift work, which have shown an increase of 235 
postprandial glucose and insulin which denotes insulin insensitivity and failure of beta cell 236 
compensation (39). Reduced insulin sensitivity reported in sleep debt could be due to an altered 237 
balance between the sympathetic (SNS) and parasympathetic nervous system (PNS) (36,39) 238 
which may influence beta cell activity indirectly via cortisol and epinephrine (36,40). High 239 
night-time cortisol has been reported to be  associated with sleep loss and insulin resistance (41). 240 
Overstimulation of the SNS as a result of the wake-promoting factor orexin (37) has been 241 
reported to result in increased glucose mobilisation and altered insulin sensitivity (42,43). It has 242 
been suggested in human studies that consumption of nutrients at inappropriate times of day 243 
results in metabolic imbalances as a result of circadian desynchrony (38). In our present study, 244 
participants were sleep deprived in both sessions, and melatonin onset was not significantly 245 
different between BL and DS, indicating that postprandial changes obtained are unlikely to be 246 
primarily due to sleep deprivation or circadian misalignment. The difference observed in glucose 247 
tolerance and insulin sensitivity could be due to the presence of melatonin in the DL session, as 248 
melatonin has been reported to inhibit insulin secretion in both rat insulinoma cells and 249 
pancreatic islets, thus influencing blood glucose levels (44,45). Furthermore, light exposure 250 
during sleep deprivation in humans has been reported to increase insulin resistance compared to 251 
sleep deprivation in the dark (46). The explanation being possible dysregulation of the SCN 252 
which coordinates peripheral organs and energy homeostasis, in addition to altered melatonin 253 
levels which have been associated with increased insulin resistance in experimental animals 254 
(47), while melatonin secretion was inversely correlated with insulin in healthy humans (48). 255 
An increase in evening light exposure and a decrease in urinary 6-sulfatoxymelatonin excretion 256 
have been associated with an increase in the prevalence of diabetes in elderly individuals (49). 257 
However, the effects of evening light exposure on glucose metabolism may be greater in the 258 
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young compared to an older population due to reduced transmission of light through the lens 259 
with ageing (50).  260 
In contrast, a human study by Rubio-Sastre et al (2014) gave exogenous melatonin prior to an 261 
oral glucose tolerance test (OGTT) in the morning and evening and resulted in raised insulin 262 
and glucose responses compared to placebo. (17). This study conflicts with our results, however 263 
this may be due to differences between the two study protocols. We utilised endogenous 264 
melatonin and a consumption of an evening meal, whereas Rubio-Sastre et al. (2014) 265 
administered a single dose of immediate release melatonin and a drink of oral glucose. The 266 
sleep-wake cycle of participants in the Rubio-Sastre (2014) study was not recorded, which could 267 
influence metabolite changes. Using a single dose of immediate release melatonin would 268 
saturate melatonin receptors with supraphysiological melatonin levels. Variability of absorption 269 
rates in oral glucose tolerance tests (OGTT) compared to our study that provide a standard 270 
evening meal could contribute to the result differences (17).  271 
Pre-prandial plasma NEFA was significantly elevated in the DL session which may be due to 272 
the physiological response to fasting itself. However, all participants had the same fasting 273 
period between lunch and the test meal during both the BL and DL sessions, and the main 274 
significant difference was clearly observed just prior to the test meal (T = 0) when melatonin 275 
levels were already high in the DL. This potentially suggests the possible stimulatory effect of 276 
melatonin on glucagon (43). Other potential mechanism could be increased sympathetic action 277 
due to endogenous melatonin inducing HSL activity (52-54). It is suggested that the major 278 
activating factor for HSL is the absence of the inhibitory effects of insulin (55). No difference 279 
in plasma TAGs could be due to the absence of melatonin effects on LPL activity. Also, it is 280 
important to note that TAG levels normally take ~9h to return to basal levels after a meal (56-281 
58).     282 
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One of the limitation of this study was that postprandial response was only measured for up to 283 
5 h after the standard evening meal which does not provide a complete profile of postprandial 284 
TAGs. Future research needs to include a longer sampling period. Further hormonal analyses 285 
such glucagon and cortisol would be interesting to determine if NEFA changes were due to 286 
glucagon effects, and to determine the role of cortisol in metabolic changes of glucose and 287 
insulin. The protocol used in this study can only explain changes due to different light sessions 288 
or endogenous melatonin action. A future study involving exogenous melatonin administration 289 
during light exposure would help to determine whether the metabolic changes seen are due to 290 
melatonin or other processes. 291 
In conclusion, this is the first study to assess the influence of bright light exposure (room light) 292 
at night on metabolic and hormonal responses in healthy young participants. Significantly 293 
higher glucose and insulin in the BL session suggests glucose intolerance and insulin 294 
insensitivity. Elevated NEFAs level in the DL session prior to the meal could either be due to 295 
the stimulatory effects of melatonin on glucagon or the inhibitory effects on insulin, resulting 296 
in higher HSL activity. Our recent results could be due to light or melatonin or a combination 297 
of the two. These results support the idea that nocturnal lifestyle, such as in night shift-work, is 298 
likely to be one of the risk factors to health in modern society, including diabetes. Further 299 
studies are needed to determine whether melatonin causes the present metabolic changes or 300 
other processes are involved. 301 
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Legends of all figures 
 
FIGURE 1 Study protocol of BL and DL sessions.  
The schematic figure represents the study protocol for a participant with plasma melatonin 
onset at 22:30h. All interventions (see key) were relative to each participants’ melatonin 
onset. 
FIGURE 2 Fluorescent light composition 
 
FIGURE 3 Plasma glucose (A), insulin (B), NEFAs (C), TAGs (D) and melatonin (E) levels 
(mean ± SEM) prior to the test meal at time = 0 in all participants (n =17) during DL ( ) and 
BL ( ) sessions. 
*P< 0.05, and ***P< 0.001.  
 
FIGURE 4 Plasma glucose (A), insulin (B), NEFAs (C), TAGS (D) and salivary melatonin 
(E) (mean ± SEM) levels prior to  and after a standard evening meal (time = 0 red dotted line) 
during DL ( ) and BL ( ) sessions in males (n=9), females (n=8) and all participants 
(n=17). 
 
FIGURE 5 Total area under the curve (TAUCs) for glucose (A), insulin (B), NEFAs (C), 
TAGs (D) and melatonin (E) (mean ± SEM) during BL and DL  sessions in all 
participant (n=17).  
*P< 0.05, **P< 0.01  
 
FIGURE 6 HOMA-IR (A) and HOMA-PP (B) (mean ± SEM) during BL and DL
sessions (n = 17).  
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Table 1 Participants demographics 
 
Male (n=9) Female (n=8) P(M Vs F) 
Age, y 22.3±3.6 22.6±2.2 0.84 
Body weight, Kg 68.4±7.9 63.8±8.5 0.26 
Height, m 1.8±1.7 1.7±0.1 0.14 
BMI, kg/m2 22.9±2.5 22.7±2.2 0.88 
Caffeine/wk 10.1±6.2 11.4±9.1 0.74 
Alcohol/wk 2.8±2.3 3.8±4.2 0.56 
PSQIa 3.3±1.2 4.1±1.5 0.24 
HÖa 51.2±8.1 52.4±10.9 0.81 
MCTQa (h) 4.7±1.2 4.9±1.1 0.87 
1 Values are mean ± SDs, 2 Calculated by 2-tailed unpaired test. BMI, body mass index; PSQI, 
Pittsburgh Sleep Quality Index; HÖ, Horne-Östberg questionnaire; MCTQ, Munich Chronotype 
Questionnaire. aValues given are those obtained during the screening session. 
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Table 2 Screening sleepand basal hormone and metabolitedata  
 BL DL P 
Sleep starta, h:min 23:54±00:14 00:18±00:14 0.1 
Sleep enda, h:min 07:21±00:10 07:35±00:09 0.1 
Sleep durationa, h 06:37±00:16 06:24±00:14 0.5 
% Sleep efficiencya 81.9±2.8 78.06±3.5 0.4 
Sleep latencya, h:min 00:35±00:12 00:48±00:12 0.5 
Fragmentation indexa 26.4±2.9 28.81±3.4 0.5 
Basal glucoseb, mmol/L 4.9 ± 0.3 4.8 ± 0.2 0.7 
Basal insulinb, pmol/L 107.± 34. 105.± 28. 0.9 
Basal NEFAsb, mmol/l 0.75±0.1 0.91±0.1 0.07 
Basal TAGsb, mmol/L 1.1±0.1 1.2±0.2 0.4 
Basal melatoninb, pg/ml 1.8±0.4 2.6±0.6 0.05 
2 Values are mean ± SEM. a Values are obtained from 7 days prior to BL and DL 
sessions.bValues represented the basal samples (T = -360min) during each clinical session. 
Sleep parameters were analysed based on data obtained from sleep diaries and actiwatch. * 
P< 0.05. 
Sleep parameters n=15 Hormone and metabolic basal data n=17 
 
TABLE 3 Carbohydrate, protein, fat, fibre and energy for each of the meals and overall 
composition of all three meals.  
Meal/g Energy Kcal Protein (g) CHO (g) Fat (g) Fibre (g) 
Breakfast 627 15 98 16 14 
Lunch 927 25 115 38 19 
Test meal“Supper” 1066 38 104 54 7 
Total 2620 78 317 105 40 
% composition*  15% 59% 19% 7% 
*Percentages were calculated proportionally from the total daily consumption 
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FIGURE 3 
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